A Single-arm, Open, Multi-center Phase II Clinical Trial of Mitoxantrone HCL Liposome Injection in Subjects With Relapsed Cutaneous T Cell Lymphomas

Trial Profile

A Single-arm, Open, Multi-center Phase II Clinical Trial of Mitoxantrone HCL Liposome Injection in Subjects With Relapsed Cutaneous T Cell Lymphomas

Discontinued
Phase of Trial: Phase II

Latest Information Update: 26 May 2017

At a glance

  • Drugs Mitoxantrone liposomal (Primary)
  • Indications Cutaneous T cell lymphoma
  • Focus Therapeutic Use
  • Sponsors CSPC ZhongQi Pharmaceutical Technology
  • Most Recent Events

    • 23 May 2017 Planned primary completion date changed from 1 Oct 2018 to 1 Oct 2017.
    • 23 May 2017 Status changed from recruiting to discontinued.
    • 13 Nov 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top